세계의 브라키테라피(소선원요법)의 시장 전망

2023년 9억 8,000만 달러(USD), 2024년 10억 7,000만 달러(USD)에서 예측 기간 동안 6.84%의 연평균 성장률(CAGR)로 2032년에는 19 4,000만 달러(USD)의 규모로 성장할 것으로 예상됩니다.

Brachytherapy Market Research Report Information, By Product (Afterloaders & Applicators, Radioactive Seeds, Electronic Brachytherapy, Imaging Systems, and Others), By Type (High Dose-Rate (HDR) Brachytherapy, Low Dose-Rate (LDR) Brachytherapy), By Technique (Interstitial Brachytherapy, Intracavitary Brachytherapy), By Indication (Prostate Cancer, Breast Cancer, Cervical Cancer, Skin Cancer, and Others), By End-Users (Hospitals & Specialty Clinics, Cancer Treatment Centers, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) Industry Forecast Till 2032

Overview of the Market

In 2023, the brachytherapy market was estimated to be worth USD 0.98 billion. With a compound annual growth rate (CAGR) of 6.84% from 2024 to 2032, the sector is expected to increase from USD 1.07 billion in 2024 to USD 1.94 billion by 2032. The global rise in cancer cases and the number of new product launches are fueling the market's expansion.

By giving cancer patients more treatment alternatives, the introduction of brachytherapy services is greatly accelerating the growth of the brachytherapy market. More patients looking for efficient substitutes for conventional radiation therapy are drawn to healthcare facilities as they broaden their offers to include this focused, minimally invasive technique. Brachytherapy is improving patient outcomes and satisfaction by directly delivering focused radiation doses to malignancies while protecting healthy tissue.

Furthermore, patients' and healthcare providers' acceptance is being aided by shorter treatment durations and fewer adverse effects. An important development in the treatment of cervical and esophageal cancers was the introduction of brachytherapy services by Karnataka Medical College and Research Institute (India) in September 2024.

Perspectives on Market Segments

Afterloaders & Applicators, Radioactive Seeds, Electronic Brachytherapy, Imaging Systems, and Others are the product-based divisions of the Brachytherapy market.

The market has been divided into two segments based on type: low dose-rate (LDR) brachytherapy and high dose-rate (HDR) brachytherapy.

The brachytherapy market has been divided into two segments based on technique: intracavity brachytherapy and interstitial brachytherapy.

The market has been divided into several segments based on indications, including skin cancer, breast cancer, prostate cancer, and cervical cancer.

The market for brachytherapy has been divided into three segments based on end users: cancer treatment centers, hospitals and specialty clinics, and others.

Regional Perspectives

The market for brachytherapy has been divided into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. In 2023, North America held the biggest market share. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the highest CAGR of 7.98%.

The market for brachytherapy is expanding quickly in North America, which is indicative of major developments in cancer treatment strategies. The need for efficient treatments has increased as cancer rates grow, especially for localized types including cervical, breast, and prostate cancers.

The market for brachytherapy in Asia-Pacific is expanding rapidly due to a number of interconnected factors. The need for efficient treatment alternatives has increased due to a notable rise in the incidence of cancer, especially breast, prostate, and cervical malignancies.

In addition, the rest of the world is further separated into South America, Africa, and the Middle East. The region's economic growth has raised healthcare expenditures, improving access to cutting-edge cancer treatment alternatives.

Key Players

Siemens Healthineers AG, Elekta, BEBIG Medical Gmbh, Becton, Dickinson and Company (US), GE Healthcare (US), Merit Medical Systems (US), Best Medical International, Inc. (US), IsoAid, LLC (US), Theragenics Corporation, Eckert & Ziegler, and others are major competitors in the brachytherapy market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research data flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research Data Flow:
  • 3.5.2 Primary Research: Number of Interviews conducted
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Type
• 3.8 DATA MODELING
  • 3.8.1 Microeconomic factor analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 Introduction of Brachytherapy Services
  • 4.2.2 Increasing incidences of cancer across the globe
  • 4.2.3 Increasing number of product launch
  • 4.2.4 Growing awareness among healthcare providers and patients about the benefits of brachytherapy
• 4.3 RESTRAINTS
  • 4.3.1 High Cost of Brachytherapy Treatment
  • 4.3.2 Competition From Alternative cancer treatment modalities
• 4.4 OPPORTUNITY
  • 4.4.1 Expansion of brachytherapy applications
  • 4.4.2 Technological Advancements associated with Brachytherapy
  • 4.4.3 Growing Expansion of Brachytherapy Manufacturing Facility and product portfolio

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 Threat of New Entrants
  • 5.1.2 Bargaining Power Of Suppliers
  • 5.1.3 Threat of Substitutes
  • 5.1.4 Bargaining Power of Buyers
  • 5.1.5 Intensity of Rivalry
• 5.2 IMPACT OF COVID-19 ON GLOBAL BRACHYTHERAPY MARKET

6 GLOBAL BRACHYTHERAPY MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 AFTERLOADERS & APPLICATORS
• 6.3 RADIOACTIVE SEEDS
• 6.4 ELECTRONIC BRACHYTHERAPY
• 6.5 IMAGING SYSTEMS
• 6.6 OTHERS

7 GLOBAL BRACHYTHERAPY MARKET, BY TYPE

• 7.1 OVERVIEW
• 7.2 HIGH DOSE-RATE (HDR) BRACHYTHERAPY
• 7.3 LOW DOSE-RATE (LDR) BRACHYTHERAPY

8 GLOBAL BRACHYTHERAPY MARKET, BY TECHNIQUE

• 8.1 OVERVIEW
• 8.2 INTERSTITIAL BRACHYTHERAPY
• 8.3 INTRACAVITARY BRACHYTHERAPY

9 GLOBAL BRACHYTHERAPY MARKET, BY INDICATION

• 9.1 OVERVIEW
• 9.2 PROSTATE CANCER
• 9.3 BREAST CANCER
• 9.4 CERVICAL CANCER
• 9.5 SKIN CANCER
• 9.6 OTHERS

10 GLOBAL BRACHYTHERAPY MARKET, BY END USER

• 10.1 OVERVIEW
• 10.2 HOSPITALS AND SPECIALTY CLINICS
• 10.3 CANCER TREATMENT CENTERS
• 10.4 OTHERS

11 GLOBAL BRACHYTHERAPY MARKET, BY REGION

• 11.1 OVERVIEW
• 11.2 NORTH AMERICA
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 EUROPE
  • 11.3.1 Germany
  • 11.3.2 France
  • 11.3.3 UK
  • 11.3.4 Italy
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 ASIA-PACIFIC
  • 11.4.1 China
  • 11.4.2 India
  • 11.4.3 Japan
  • 11.4.4 South Korea
  • 11.4.5 Australia
  • 11.4.6 Rest of Asia-Pacific
• 11.5 REST OF THE WORLD
  • 11.5.1 Middle East
    • 11.5.1.1 SAUDI ARABIA
    • 11.5.1.2 UNITED ARAB EMIRATES
    • 11.5.1.3 OMAN
    • 11.5.1.4 QATAR
    • 11.5.1.5 TURKEY
    • 11.5.1.6 KUWAIT
    • 11.5.1.7 BAHRAIN
    • 11.5.1.8 REST OF MIDDLE EAST
  • 11.5.2 Africa
    • 11.5.2.1 SOUTH AFRICA
    • 11.5.2.2 MOROCCO
    • 11.5.2.3 REST OF AFRICA
  • 11.5.3 South America
    • 11.5.3.1 BRAZIL
    • 11.5.3.2 ARGENTINA
    • 11.5.3.3 REST OF SOUTH AMERICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 MARKET SHARE ANALYSIS,
• 12.3 COMPETITOR DASHBOARD
• 12.4 PUBLIC PLAYERS STOCK SUMMARY
• 12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 12.6.1 PRODUCT LAUNCH
  • 12.6.2 PRODUCT APPROVAL
  • 12.6.3 ACQUISITION

13 COMPANY PROFILES

• 13.1 ELEKTA
  • 13.1.1 COMPANY OVERVIEW
  • 13.1.2 FINANCIAL OVERVIEW
  • 13.1.3 PRODUCT OFFERED
  • 13.1.4 KEY DEVELOPMENTS
  • 13.1.5 SWOT ANALYSIS
  • 13.1.6 KEY STRATEGIES
• 13.2 BEBIG MEDICAL GMBH
  • 13.2.1 OMPANY OVERVIEW
  • 13.2.2 FINANCIAL OVERVIEW
  • 13.2.3 PRODUCTS OFFERED
  • 13.2.4 KEY DEVELOPMENTS
  • 13.2.5 KEY STRATEGIES
• 13.3 THERAGENICS CORPORATION
  • 13.3.1 COMPANY OVERVIEW
  • 13.3.2 FINANCIAL OVERVIEW
  • 13.3.3 PRODUCTS OFFERED
  • 13.3.4 KEY DEVELOPMENTS
  • 13.3.5 KEY STRATEGIES
• 13.4 SIEMENS HEALTHINEERS AG
  • 13.4.1 COMPANY OVERVIEW
  • 13.4.2 FINANCIAL OVERVIEW
  • 13.4.3 PRODUCTS OFFERED
  • 13.4.4 KEY DEVELOPMENTS
  • 13.4.5 SWOT ANALYSIS
  • 13.4.6 KEY STRATEGIES
• 13.5 ECKERT & ZIEGLER
  • 13.5.1 COMPANY OVERVIEW
  • 13.5.2 FINANCIAL OVERVIEW
  • 13.5.3 PRODUCTS OFFERED
  • 13.5.4 KEY DEVELOPMENTS
  • 13.5.5 SWOT ANALYSIS
  • 13.5.6 KEY STRATEGIES
• 13.6 BECTON, DICKINSON AND COMPANY
  • 13.6.1 COMPANY OVERVIEw
  • 13.6.2 FINANCIAL OVERVIEW
  • 13.6.3 PRODUCTS OFFERED
  • 13.6.4 KEY DEVELOPMENTS
  • 13.6.5 SWOT ANALYSIS
  • 13.6.6 KEY STRATEGIES
• 13.7 GE HEALTHCARE
  • 13.7.1 COMPANY OVERVIEW
  • 13.7.2 FINANCIAL OVERVIEW
  • 13.7.3 PRODUCTS OFFERED
  • 13.7.4 KEY DEVELOPMENTS
  • 13.7.5 SWOT ANALYSIS
  • 13.7.6 KEY STRATEGIES
• 13.8 MERIT MEDICAL SYSTEMS
  • 13.8.1 COMPANY OVERVIEW
  • 13.8.2 FINANCIAL OVERVIEW
  • 13.8.3 PRODUCTS OFFERED
  • 13.8.4 KEY DEVELOPMENTS
  • 13.8.5 KEY STRATEGIES
• 13.9 BEST MEDICAL INTERNATIONAL, INC.
  • 13.9.1 COMPANY OVERVIEW
  • 13.9.2 FINANCIAL OVERVIEW
  • 13.9.3 PRODUCTS OFFERED
  • 13.9.4 KEY DEVELOPMENTS
  • 13.9.5 KEY STRATEGIES
• 13.10 ISOAID, LLC
  • 13.10.1 COMPANY OVERVIEW
  • 13.10.2 FINANCIAL OVERVIEW
  • 13.10.3 PRODUCTS OFFERED
  • 13.10.4 KEY DEVELOPMENTS
  • 13.10.5 KEY STRATEGIES

14 DATA CITATIONS